Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region

Launched by CENTRE DE RECHERCHE MÉDICALE DE LAMBARÉNÉ · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on studying multidrug-resistant tuberculosis (MDR-TB) in Central Africa. MDR-TB is a serious form of tuberculosis that does not respond to standard treatments, making it harder to control. The researchers want to understand the different strains of this disease and how they spread, especially since some strains are becoming resistant to new treatments. By looking at the genetic makeup of these strains, the study aims to improve how we manage and treat MDR-TB in the region.

To participate in this trial, individuals must be at least 8 years old and have tested positive for TB using a specific test called GeneXpert. Participants will need to provide a sample of their sputum (the mucus from their lungs) for testing. The study is not yet recruiting participants, but once it starts, those who join can expect to contribute to important research that may help improve treatments for TB in the future. It's also important to note that samples need to meet certain quality standards, so not all samples will be eligible for the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All GeneXpert positive TB patients and participants who provide written informed consent will be screened for the study. Participants aged above 8 who can provide sputum will also be screened.
• • Patients enrolled in the tuberculosis epidemiology (TB-EPI) study and eligible for MESTCAR will be enrolled without any additional consent form as the data to be collected for the two studies will be shared and no additional process is needed.
• Exclusion Criteria:
• • Samples which do not meet the quality criteria.
• • Samples not enough to perform all of the laboratory process
• • Samples contaminated